← Leaderboards
James J Mule
University Of Michigan At Ann Arbor
$10,173,865
Attributed
$10,852,540
Total exposure
14
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722.3K · FY2007–21$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$14,812,821 · 15
By mechanism
R01$8,433,917 · 5
P01$3,960,281 · 1
T32$1,542,519 · 2
P30$592,899 · 2
P50$278,424 · 1
M01$4,781 · 4
Top collaborators
- Patrick Hwu4 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Stephen B Gruber$33,126,242
- Weiping Zou$38,970,401
- Maureen Agnes Sartor$7,415,011
- Nisha J D'silva$14,161,982
- Miriam H Meisler$27,545,261
Others in their field
Top investigators on “Dendritic Cells”
- Barton F Haynes · Duke University$112,608,041
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- James C. Paulson · Scripps Research Institute$41,568,802
- Ulrich H Von Andrian · Harvard Medical School$32,521,007
- Donald L Morton · John Wayne Cancer Institute$29,042,629
Research focus
Dendritic CellsClinical ResearchNeoplasm /Cancer ImmunotherapyLaboratoriesHuman Therapy EvaluationMalignant NeoplasmsHuman SubjectT-LymphocyteVaccine DevelopmentCellsNeoplasm /Cancer VaccineMelanomaClinical TrialsFundingImmunotherapyCollaborationsMemberBaseDesignPre-ClinicalGenesGene TherapyAntigen-Presenting CellsVaccines
Grant awards (60)
Cell Therapies Core$116,055
P30 · FY2021 · CA · contact PI
Cell Therapies Core$116,051
P30 · FY2020 · CA · contact PI
Cell Therapies Core$4,498
P30 · FY2020 · CA · contact PI
Cell Therapies Core$112,208
P30 · FY2019 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$340,821
R01 · FY2018 · CA
Cell Therapies Core$114,494
P30 · FY2018 · CA · contact PI
Cell Therapies Core$8,050
P30 · FY2018 · CA · contact PI
Cell Therapies Core$3,753
P30 · FY2018 · CA · contact PI
Cell Therapies Core$3,293
P30 · FY2018 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$337,982
R01 · FY2017 · CA
Cell Therapies Core$114,497
P30 · FY2017 · CA · contact PI
Career Development Program$60,136
P50 · FY2017 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$337,726
R01 · FY2016 · CA
Career Development Program$48,567
P50 · FY2016 · CA · contact PI
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy$340,821
R01 · FY2015 · CA
Career Development Program$56,663
P50 · FY2015 · CA · contact PI
Designing Lymph Nodes for Cancer Immunotherapy$326,045
R01 · FY2014 · CA · contact PI
Career Development Program$56,654
P50 · FY2014 · CA · contact PI
Designing Lymph Nodes for Cancer Immunotherapy$315,961
R01 · FY2013 · CA · contact PI
Career Development Program$56,404
P50 · FY2013 · CA · contact PI
Designing Lymph Nodes for Cancer Immunotherapy$336,129
R01 · FY2012 · CA · contact PI
Designing Lymph Nodes for Cancer Immunotherapy$336,129
R01 · FY2011 · CA · contact PI
The Significance of MARCO Expression by Tumor-Pulsed Dendritic Cells$375,750
R01 · FY2010 · CA · contact PI
Designing Lymph Nodes for Cancer Immunotherapy$346,525
R01 · FY2010 · CA · contact PI
The Significance of MARCO Expression by Tumor-Pulsed Dendritic Cells$374,438
R01 · FY2009 · CA · contact PI
The Significance of MARCO Expression by Tumor-Pulsed Dendritic Cells$373,500
R01 · FY2008 · CA · contact PI
The Significance of MARCO Expression by Tumor-Pulsed Dendritic Cells$366,750
R01 · FY2007 · CA · contact PI
THERAPEUTIC STUDIES--DENDRITIC CELL BASED CANCER VACCINE$374,333
R01 · FY2004 · CA
Use of Human Dendritic Cells &Chemokines to Enhance Immune Response to Cancer$4,575
M01 · FY2004 · RR
Cellular Vaccines for Cancer Therapy$1,171,386
P01 · FY2003 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$409,948
R01 · FY2003 · CA
THERAPEUTIC STUDIES--DENDRITIC CELL BASED CANCER VACCINE$336,674
R01 · FY2003 · CA
Surgical Oncology Research Training Program$273,470
T32 · FY2003 · CA
RESEARCH TRAINING IN TRANSLATIONAL TUMOR IMMUNOLOGY$231,360
T32 · FY2003 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$35,234
R01 · FY2003 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$22,871
R01 · FY2003 · CA
Cellular Vaccines for Cancer Therapy$1,404,012
P01 · FY2002 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$338,487
R01 · FY2002 · CA
THERAPEUTIC STUDIES--DENDRITIC CELL BASED CANCER VACCINE$326,871
R01 · FY2002 · CA
Surgical Oncology Research Training Program$287,760
T32 · FY2002 · CA
RESEARCH TRAINING IN TRANSLATIONAL TUMOR IMMUNOLOGY$264,865
T32 · FY2002 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$116,691
R01 · FY2002 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$75,820
R01 · FY2002 · CA
CD34+ cells for hematologic rescue of B-cell malignancy patients$0
M01 · FY2002 · RR
PILOT--TUMOR IMMUNOLOGY$0
P30 · FY2002 · CA
KLH PULSED DENDRITIC CELLS IN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT$0
M01 · FY2002 · RR
HUMAN DENDRITIC CELLS AND CHEMOKINES TO ENHANCE IMMUNE RESPONSE TO CANCER$0
M01 · FY2002 · RR
Cellular Vaccines for Cancer Therapy$1,384,883
P01 · FY2001 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$328,940
R01 · FY2001 · CA
ANTIHER2 CHIMERIC TCR GENE MODIFIED HSC$326,955
R01 · FY2001 · CA
THERAPEUTIC STUDIES--DENDRITIC CELL BASED CANCER VACCINE$317,436
R01 · FY2001 · CA
Surgical Oncology Research Training Program$250,525
T32 · FY2001 · CA
RESEARCH TRAINING IN TRANSLATIONAL TUMOR IMMUNOLOGY$234,539
T32 · FY2001 · CA
PILOT--TUMOR IMMUNOLOGY$0
P30 · FY2001 · CA
DIRECT INTRATUMORAL ADMINISTRATION OF DENDRITIC CELLS$320,698
R01 · FY2000 · CA
THERAPEUTIC STUDIES--DENDRITIC CELL BASED CANCER VACCINE$309,209
R01 · FY2000 · CA
ANTIHER2 CHIMERIC TCR GENE MODIFIED HSC$285,173
R01 · FY2000 · CA
KLH PULSED DENDRITIC CELLS IN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT$206
M01 · FY2000 · RR
CD34+ cells for hematologic rescue of B-cell malignancy patients$0
M01 · FY2000 · RR
HUMAN DENDRITIC CELLS AND CHEMOKINES TO ENHANCE IMMUNE RESPONSE TO CANCER$0
M01 · FY2000 · RR